Cell Line-Specific In Vitro Effects of Boric Acid and Meis1i-2 in Leukemia Cells: Apoptosis, Cell-Cycle Modulation,...

Area of Science:

• Hematological Malignancies
• Cancer Therapeutics
• Molecular Biology

Background:

• Leukemia is a complex hematological malignancy driven by genetic and environmental factors, characterized by uncontrolled hematopoietic cell proliferation.
• Existing leukemia treatments are limited by drug resistance and significant off-target toxicity, necessitating the development of novel therapeutic approaches.
• This study investigates the potential of boric acid (BA) and Myeloid Ecotropic Viral Integration Site 1 Inhibitor-2 (Meis1i-2) as novel anti-leukemic agents.

Purpose of the Study:

• To evaluate the in vitro effects of boric acid (BA) and Myeloid Ecotropic Viral Integration Site 1 Inhibitor-2 (Meis1i-2) on leukemia cell lines.
• To assess the individual and combined impacts of BA and Meis1i-2 on apoptosis, cell-cycle distribution, and gene expression.
• To determine the potential synergistic or antagonistic interactions between BA and Meis1i-2 in leukemia treatment.

Main Methods:

• Three leukemia cell lines (K562, RS4-11, CCRF-CEM) were treated with varying concentrations of BA and Meis1i-2, individually and in combination.
• Apoptosis was quantified using Annexin V-FITC/PI staining and flow cytometry.
• Cell cycle distribution was analyzed using Hoechst 33342 and Pyronin Y staining followed by flow cytometry.
• Quantitative RT-PCR (qRT-PCR) was used to measure the transcript levels of apoptosis- and cell cycle-related genes.

Main Results:

• Both BA and Meis1i-2 demonstrated concentration- and cell-line-dependent effects on viability, apoptosis, and cell-cycle distribution at 72 hours.
• Treatment induced apoptotic changes and altered the distribution of G1, S, and G2/M phases in a cell-line-specific manner.
• Chou-Talalay analysis in RS4-11 cells indicated antagonistic interactions (CI > 1) between BA and Meis1i-2 at the tested concentrations, suggesting concentration-specific activity rather than synergy.

Conclusions:

• Boric acid and Meis1i-2 exhibit measurable anti-leukemic effects by inducing apoptosis and modulating cell cycle progression.
• The combination of BA and Meis1i-2 did not show synergistic effects under the tested experimental conditions, exhibiting antagonism instead.
• Further research involving expanded dose matrices, protein-level validation, and in vivo studies is warranted to fully elucidate the therapeutic potential of these agents.